XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:

 

 SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES

   2024   2023 
   For the year ended December 31, 
   2024   2023 
         
License and other revenues  $—   $3,500 
           
Research and development costs          
Salaries & related costs   15,345    11,373 
Non-cash stock-based compensation   1,561    1,086 
Other research and development costs (a)   17,454    18,632 
Total research and development costs   34,360    31,091 
           
General and administrative costs          
Salaries & related costs  $10,729   $6,942 
Non-cash stock-based compensation   5,067    3,682 
Pre-commercial preparation costs   4,818    1,224 
Other general and administrative costs (b)   9,237    7,156 
Total general and administrative costs  $29,851   $19,004 
           
Other segment items (c)   (477)   7,593 
Net loss  $(63,734)  $(54,188)

 

(a) Other research and development expenses include, but are not limited to lab supplies, preclinical and development costs, clinical trial costs, manufacturing and manufacturing facility costs, costs associated with regulatory approvals, depreciation on lab supplies and manufacturing facilities, and consultant-related expenses.
(b) Other general and administrative expenses primarily consist of office facility costs, public reporting company related costs, professional fees (e.g., legal expenses) and other general operating expenses not otherwise included in research and development expenses.
(c) Other segment items includes royalties, interest income, interest expense, change in fair value of warrant and derivative liabilities and other income.